Physician

Adel Obaji, M.D.

According to 2025 Medicare claims, Adel Obaji, M.D. (NPI: 1124073127) practices pulmonary disease in the Rochester, NY market, with the plurality of this provider's patient population coming from Monroe, NY. This provider's primary affiliated billing organization is ROCHESTER GENERAL HOSPITAL (NPI: 1356412712; TIN: 160743134) and primary practice location at 14621-3001. Obaji is affiliated with the Rochester Regional Health ACO, Inc. (ACO ID: A3476), participating under the MSSP model.

Obaji's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 149 traditional Medicare patients, billed 429 HCPCS/CPT codes, and received $40,298 in Medicare payments. The top billing code was 99291 (Critical care, first 30-74 minutes). Part D data shows 940 prescription claims across 152 beneficiaries totaling $852,220 in drug costs, led by Ofev (Nintedanib Esylate). DME data shows 79 claims. Open Payments data shows 2 records totaling $56. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $173,856 to $852,220. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $3,457 and ending at $5,492.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	224	546	$44,831
2016	210	529	$39,234
2017	225	544	$53,574
2018	227	564	$47,492
2019	188	474	$37,896
2020	169	441	$44,306
2021	148	432	$42,661
2022	174	483	$44,478
2023	156	392	$31,462
2024	149	429	$40,298

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	89	549	$173,856
2016	115	757	$238,145
2017	107	623	$355,022
2018	127	761	$462,862
2019	150	835	$604,614
2020	132	756	$682,748
2021	168	886	$932,531
2022	161	849	$766,933
2023	144	928	$881,824
2024	152	940	$852,220

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	95	$3,350
2016	N/R	69	$3,407
2017	N/R	71	$2,540
2018	N/R	39	$11,705
2019	N/R	55	$11,957
2020	N/R	24	$788
2021	N/R	52	$2,042
2022	N/R	72	$3,756
2023	N/R	94	$5,750
2024	N/R	79	$5,002

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99291	Critical care, first 30-74 minutes	54	152	$169
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	36	72	$63
94727	Test to determine lung volumes using gas dilution or washout	22	24	$9
94060	Test to measure expiratory airflow and volume changes before and after medication administration	17	17	$8
94729	Test to examine how well the lungs exchange gases	28	30	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ofev	Nintedanib Esylate	28	1,020	$428,709
Fasenra Pen	Benralizumab	14	784	$73,289
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	80	3,240	$68,736
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	44	1,620	$34,484
Spiriva Respimat	Tiotropium Bromide	34	1,140	$19,810

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	52	$4,706
E0431	Portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing	Y	N/R	15	$210
J7614	Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg	N	N/R	12	$86

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$56	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adel Obaji, M.D.?

Tedicare shows public-source Medicare data for Adel Obaji, M.D. (NPI 1124073127), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adel Obaji, M.D. have ACO affiliation data?

Adel Obaji, M.D. is shown with ACO affiliation data for Rochester Regional Health ACO, Inc. (MSSP, ACO ID A3476).

What billing organization is linked to Adel Obaji, M.D.?

Adel Obaji, M.D. is linked to ROCHESTER GENERAL HOSPITAL (billing NPI 1356412712) in the available physician profile data.

Does Adel Obaji, M.D. have Open Payments data?

Adel Obaji, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.